45 results found.

Wet Macular Degeneration Clinical Trial using Ranibizumab; OZURDEX

McMaster University - Recruiting 18 years or older.
- OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab.
Ranibizumab; OZURDEX

Age Related Macular Degeneration Clinical Trial using Ranibizumab

McMaster University - Recruiting 18 years or older.
- Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes.
Ranibizumab

Wet Age-related Macular Degeneration Clinical Trial using VEGF Trap-Eye (BAY86-5321)

Bayer - Recruiting N/A or older.
- PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea®) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration.
VEGF Trap-Eye (BAY86-5321)

Age-Related Macular Degeneration Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years or older.
- Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration.

Neovascular Age-related Macular Degeneration Clinical Trial using Aflibercept (EYLEA)

Hadassah Medical Organization - Recruiting 50 years or older.
- A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD)..
Aflibercept (EYLEA)

Age-related Macular Degeneration; Polypoidal Choroidal Vasculopat Clinical Trial using Ranibizumab; Verteporfin PDT; Sham PDT

Novartis - Recruiting 18 years or older.
- A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV.
Ranibizumab; Verteporfin PDT; Sham PDT

Macular Degeneration Clinical Trial using RO6867461

Hoffmann-La Roche - Recruiting 50 years or older.
- A Multiple-Center, Non-Randomized, Open-Label, Single-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration..
RO6867461

Macular Degeneration, Age-related Maculopathies, Age-related Macu Clinical Trial using rAAV.sFlt-1; Control (ranibizumab alone)

Lions Eye Institute, Perth, Western Australia - Recruiting 55 years or older.
- A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD).
rAAV.sFlt-1; Control (ranibizumab alone)

Age Related Macular Degeneration Clinical Trial using 3 dose cohorts gene therapy

Oxford BioMedica - Recruiting 50 years or older.
- A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration.
3 dose cohorts gene therapy

Macular Degeneration Clinical Trial using VEGF Trap-Eye (BAY86-5321)

Bayer - Recruiting N/A or older.
- Special Drug Use Investigation of EYLEA for Quality of Life.
VEGF Trap-Eye (BAY86-5321)

Macular Degeneration Clinical Trial using VEGF Trap-Eye (BAY86-5321)

Bayer - Recruiting N/A or older.
- Special Drug Use Investigation of EYLEA for AMD.
VEGF Trap-Eye (BAY86-5321)

Age-Related Macular Degeneration, or AMD Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 60 years to 90 years.
- AMD Phenotype and Genotype Study (APGS).

AMD, or Age- Related Macular Degeneration Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years to 85 years.
- Age-Related Eye Disease Study 2 (AREDS2) Ancillary Spectral Domain Optical Coherence Tomography (A2A_SDOCT) Extension Study.

Diabetic Retinopathy, Age-Related Macular Degeneration (AMD), or Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 4 years or older.
- Epigenetics, Molecular Genetics, and Biomarkers of Degenerative and Inflammatory Ocular Diseases.

Age-Related Macular Degeneration (AMD) Clinical Trial using PAN-90806 Ophthalmic Solution

PanOptica, Inc. - Recruiting 50 years or older.
- A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD).
PAN-90806 Ophthalmic Solution

Geographic Atrophy Clinical Trial using ACU-4429; Placebo

Acucela Inc. - Recruiting 55 years or older.
- A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration.
ACU-4429; Placebo

Exudative Age-Related Macular Degeneration Clinical Trial using ESBA1008 solution; Ranibizumab

Alcon Research - Recruiting 50 years or older.
- A Prospective, Two Cohort, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration.
ESBA1008 solution; Ranibizumab

Age Related Macular Degeneration Clinical Trial

Duke University - Recruiting 18 years or older.
- Pilot Study Evaluating Visual Function Impairments in Patients With Dry Age-related Macular Degeneration.

Age-related Macular Degeneration, or Choroidal Neovascularization Clinical Trial using Ranibizumab 0.5mg

Novartis - Recruiting 50 years or older.
- A 12-month, Phase IIIb, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular AMD.
Ranibizumab 0.5mg

Age-related Macular Degeneration Clinical Trial using Printed materials; Video

University Health Network, Toronto - Recruiting 18 years or older.
- A Visual Approach to Reducing Anxiety and Improving Knowledge Transfer for Patients Receiving Intravitreal Injections.
Printed materials; Video

Wet Age-related Macular Degeneration Clinical Trial

Novartis - Recruiting 50 years or older.
- A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics.

Age Related Macular Degeneration, Macular Degeneration, or AMD Clinical Trial using HuCNS-SC cells

StemCells, Inc. - Recruiting 50 years or older.
- Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration.
HuCNS-SC cells

Visual Impairment Due to Neovascular AMD Clinical Trial using Ranibizumab; Aflibercept

Novartis - Recruiting 18 years or older.
- A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD).
Ranibizumab; Aflibercept

Geographic Atrophy, or Age-related Macular Degeneration Clinical Trial using LFG316; Sham

Novartis - Recruiting 55 years to 90 years.
- A Multicenter, Randomized, Sham-control, Proof-of-concept Study of Intravitreal LFG316 in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration.
LFG316; Sham

Age Related Macular Degeneration Clinical Trial using intravitreal injection of autologous bone marrow stem cells

University of Sao Paulo - Recruiting 55 years to 80 years.
- Intravitreal Bone Marrow-Derived Stem Cells in Patients With Advanced Age-related Macular Degeneration.
intravitreal injection of autologous bone marrow stem cells

Age Related Cognitive Decline, or Age Related Macular Degeneratio Clinical Trial using Walnuts; habitual diet

Loma Linda University - Recruiting 65 years to 75 years.
- Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial.
Walnuts; habitual diet

Age-Related Macular Degeneration Clinical Trial using DE-120

Santen Inc. - Recruiting 55 years or older.
- A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration.
DE-120

Age-Related Macular Degeneration, or Neovascularization, Choroida Clinical Trial using Intravitreal dexamethasone and intravitreal ranibizumab; Intravitreal ranibizumab

Medical University of Vienna - Recruiting 50 years or older.
- Comparison of Intravitreal Dexamethasone With Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Monotherapy in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration A Prospective, Randomized, Clinical Study.
Intravitreal dexamethasone and intravitreal ranibizumab; Intravitreal ranibizumab

Age-Related Macular Degeneration Clinical Trial using E10030; ranibizumab; E10030 sham intravitreal injection

Ophthotech Corporation - Recruiting 50 years or older.
- A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of FovistaT (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentisr Compared to Lucentisr Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration..
E10030; ranibizumab; E10030 sham intravitreal injection

Cataract, or Macular Degeneration Clinical Trial using selenium; vitamin E; vitamin E placebo; selenium placebo

Southwest Oncology Group - Recruiting 50 years or older.
- S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE).
selenium; vitamin E; vitamin E placebo; selenium placebo

Age Related Macular Degeneration Clinical Trial

NJ Retina - Recruiting 65 years to 90 years.
- Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

Age-related Macular Degeneration Clinical Trial using Sildenafil citrate

Duke University - Recruiting 65 years or older.
- Effects of Sildenafil on Choroidal Thickness in Age-Related Macular Degeneration.
Sildenafil citrate

Macular Degeneration Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years or older.
- Evaluation of Single Nucleotide Polymorphism (SNP) in Patients With and Subjects Without Age-Related Macular Degeneration (AMD).

Macular Degeneration Clinical Trial

Department of Veterans Affairs - Recruiting 40 years to 80 years.
- Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration.

Stargardts, Retinitis Pigmentosa, Age-related Macular Degeneratio Clinical Trial using Retinal imaging

University of Pennsylvania - Recruiting 7 years or older.
- High Resolution Retinal Imaging.
Retinal imaging

Macular Degeneration Clinical Trial using ALG 1001

Allegro Ophthalmics, LLC - Recruiting 50 years or older.
- A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration.
ALG 1001

Age-related Macular Degeneration, or Depression Clinical Trial using BA-LVR; ST-LVR

Thomas Jefferson University - Recruiting 65 years or older.
- Low Vision Depression Prevention Trial for Age Related Macular Degeneration.
BA-LVR; ST-LVR

Exudative Age-related Macular Degeneration Clinical Trial using Intravitreal injection of Aflibercept

Stanford University - Recruiting 50 years or older.
- Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration.
Intravitreal injection of Aflibercept

Age Related Macular Degeneration Clinical Trial

Royal Liverpool University Hospital - Recruiting 50 years or older.
- Study of Macular Function During Anti-VEGF Treatment.

Age Related Macular Degeneration Clinical Trial

Medical University of Vienna - Recruiting 18 years to 90 years.
- Macular Pigment Optical Density in Healthy Subjects.

Age-Related Neovascular Macular Degeneration Clinical Trial using bevacizumab; ranibizumab

Klinikum Bremen-Mitte, gGmbH - Recruiting 50 years or older.
- Prevention of Vision Loss in Patients With Age-Related Neovascular Macular Degeneration by Intravitreal Injection of Bevacizumab and Ranibizumab in a Typical Outpatient Setting.
bevacizumab; ranibizumab

Age-Related Macular Degeneration, or Stress Clinical Trial using Preoperative information and perioperative care

University Hospital Tuebingen - Recruiting 18 years or older.
- Fear of Intravitreal Injection - Assessment of Psychological Strain and Potential Contributing Factors.
Preoperative information and perioperative care

Age-Related Macular Degeneration Clinical Trial using reduced fluence photodynamic therapy with Visudyne; Lucentis

Barnes Retina Institute - Recruiting 50 years or older.
- An Open-Label, Single-Site, Comparative, Pilot Study of the Treatment Effects of Combination Therapy of Lucentis (Ranibizumab) Plus Reduced Fluence Photodynamic Therapy With Visudyne in Patients With Exudative Age-Related Macular Degeneration (AMD).
reduced fluence photodynamic therapy with Visudyne; Lucentis

Age-Related Macular Degeneration, or Choroidal Neovascularization Clinical Trial

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery - Recruiting 55 years or older.
- Reliability of Threshold Algorithm in Age-Related Macular Degeneration: Stratus Versus Cirrus OCT.